| Customization: | Available |
|---|---|
| Transport Package: | Drum |
| Specification: | 99% |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Alogliptin benzoate is a medication used to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is a class of drugs known as "gliptins." Alogliptin works by inhibiting the DPP-4 enzyme, which is responsible for breaking down certain hormones in the body that help regulate blood sugar. By inhibiting DPP-4, alogliptin increases the levels of these hormones, known as incretins (glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)), which in turn stimulates the pancreas to produce more insulin and reduces the liver's glucose production, thereby helping to control blood sugar levels.
Alogliptin was first approved by the FDA in January 2013 and is available under various brand names such as Incresync, Kazano, Nesina, and Oseni. It is typically prescribed as an adjunct to diet and exercise. The standard dose for patients with type 2 diabetes is 25 mg once daily, taken orally without regard to food intake. However, dosage adjustments may be necessary for patients with renal impairment.
The drug is generally well-tolerated, with common side effects including nasopharyngitis, headache, and upper respiratory tract infection. There have been reports of serious hypersensitivity reactions, including anaphylaxis, and potential risks of heart failure, although the latter is a subject of ongoing research with mixed results from clinical trials.
){kind=link}